Literature DB >> 22048926

The effect of inappropriate therapy on bacteremia by ESBL-producing bacteria.

F G De Rosa1, N Pagani, L Fossati, S Raviolo, C Cometto, P Cavallerio, C Parlato, E Guglielmi, R Serra, G Di Perri.   

Abstract

OBJECTIVE: To describe the impact of empiric appropriate treatment and the risk factors associated with mortality in patients with bacteremia by E. coli, K. pneumoniae and P. mirabilis producing ESBL.
METHODS: Data were reviewed in an 8-year retrospective study, and 128 bacteremias were found: 80 caused by E. coli (62.5%), 28 by K. pneumoniae (21.9%) and 20 by P. mirabilis (18.6%).
RESULTS: The initial antibiotic treatment, administered within 72 h after the first positive blood culture, was appropriate with carbapenems or other antimicrobial agents with documented in vitro sensitivity in 53.8 and 16% of patients, respectively. The overall mortality 21 days after diagnosis was 17.2%, and it was 14.9 and 35.2% for patients adequately and inadequately treated, respectively. At univariate analysis the p value for mortality with and without appropriate treatment was 0.05, and significant differences were found only for previous positive blood cultures (p = 0.004) and presence of septic shock at diagnosis (p = 0.006).
CONCLUSION: In this case series there was a high rate of initial appropriate empiric treatment, and only a marginal impact on mortality was found with regard to appropriate and inappropriate treatment. This report shows that the knowledge of ESBL-producing characteristics varies widely among the different case series for reasons that still have to be clarified.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22048926     DOI: 10.1007/s15010-011-0201-x

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  17 in total

1.  Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment.

Authors:  Mario Tumbarello; Maurizio Sanguinetti; Eva Montuori; Enrico M Trecarichi; Brunella Posteraro; Barbara Fiori; Rita Citton; Tiziana D'Inzeo; Giovanni Fadda; Roberto Cauda; Teresa Spanu
Journal:  Antimicrob Agents Chemother       Date:  2007-03-26       Impact factor: 5.191

2.  Clinical impact of infections caused by ESBL-producing E. coli and K. pneumoniae.

Authors:  Axel Kola; Oliver Maciejewski; Dorit Sohr; Stefan Ziesing; Petra Gastmeier
Journal:  Scand J Infect Dis       Date:  2007-06-21

Review 3.  The 2011 revolution in antimicrobial susceptibility testing and reporting: what the ICU physicians need to know.

Authors:  C Tascini; P Malacarne; M Langer; F Menichetti; G M Rossolini
Journal:  Minerva Anestesiol       Date:  2011-05-26       Impact factor: 3.051

4.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.

Authors:  M E Charlson; P Pompei; K L Ales; C R MacKenzie
Journal:  J Chronic Dis       Date:  1987

5.  Urinary tract infections caused by multi-drug resistant Proteus mirabilis: Risk factors and clinical outcomes.

Authors:  K Cohen-Nahum; L Saidel-Odes; K Riesenberg; F Schlaeffer; A Borer
Journal:  Infection       Date:  2009-12-07       Impact factor: 3.553

6.  Bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy.

Authors:  Cheol-In Kang; Sung-Han Kim; Wan Beom Park; Ki-Deok Lee; Hong-Bin Kim; Eui-Chong Kim; Myoung-Don Oh; Kang-Won Choe
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

7.  Bacteremia due to extended-spectrum beta -lactamase-producing Escherichia coli in the CTX-M era: a new clinical challenge.

Authors:  Jesús Rodríguez-Baño; Maria D Navarro; Luisa Romero; Miguel A Muniain; Marina de Cueto; María J Ríos; José R Hernández; Alvaro Pascual
Journal:  Clin Infect Dis       Date:  2006-10-25       Impact factor: 9.079

8.  Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases.

Authors:  David L Paterson; Wen-Chien Ko; Anne Von Gottberg; Sunita Mohapatra; Jose Maria Casellas; Herman Goossens; Lutfiye Mulazimoglu; Gordon Trenholme; Keith P Klugman; Robert A Bonomo; Louis B Rice; Marilyn M Wagener; Joseph G McCormack; Victor L Yu
Journal:  Clin Infect Dis       Date:  2004-06-08       Impact factor: 9.079

9.  Analysis of 4758 Escherichia coli bacteraemia episodes: predictive factors for isolation of an antibiotic-resistant strain and their impact on the outcome.

Authors:  M Ortega; F Marco; A Soriano; M Almela; J A Martínez; A Muñoz; J Mensa
Journal:  J Antimicrob Chemother       Date:  2009-01-06       Impact factor: 5.790

10.  Risks factors for infections with extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae at a tertiary care university hospital in Switzerland.

Authors:  S P Kuster; B Hasse; V Huebner; V Bansal; R Zbinden; C Ruef; B Ledergerber; R Weber
Journal:  Infection       Date:  2010-01-27       Impact factor: 3.553

View more
  13 in total

1.  Association between dementia and reduced walking ability and 30-day mortality in patients with extended-spectrum beta-lactamase-producing Escherichia coli bacteremia.

Authors:  G Chapelet; A S Boureau; A Dylis; G Herbreteau; S Corvec; E Batard; G Berrut; L de Decker
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-08-12       Impact factor: 3.267

2.  Managing ESBL-producing Enterobacteriaceae-related urinary tract infection in primary care: a tool kit for general practitioners.

Authors:  Aurélie Zucconi; Johan Courjon; Christophe Maruéjouls; Fabrice Saintpère; Nicolas Degand; Lilli Pandiani; Christian Pradier; Véronique Mondain
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-03-28       Impact factor: 3.267

3.  Impact of appropriateness of empiric therapy on outcomes in community-onset bacteremia by extended-spectrum-β-lactamase producing Escherichia coli and Klebisella pneumoniae definitively treated with carbapenems.

Authors:  E-J Joo; D A Park; N R Lee; S-Y Moon; J-K Choi; J-H Ko; K R Peck
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-06-23       Impact factor: 3.267

4.  Appropriateness of empirical treatment and outcome in bacteremia caused by extended-spectrum-β-lactamase-producing bacteria.

Authors:  Florine N J Frakking; Wouter C Rottier; J Wendelien Dorigo-Zetsma; Jarne M van Hattem; Babette C van Hees; Jan A J W Kluytmans; Suzanne P M Lutgens; Jan M Prins; Steven F T Thijsen; Annelies Verbon; Bart J M Vlaminckx; James W Cohen Stuart; Maurine A Leverstein-van Hall; Marc J M Bonten
Journal:  Antimicrob Agents Chemother       Date:  2013-04-22       Impact factor: 5.191

Review 5.  Incidence and outcome of inappropriate in-hospital empiric antibiotics for severe infection: a systematic review and meta-analysis.

Authors:  Kristel Marquet; An Liesenborgs; Jochen Bergs; Arthur Vleugels; Neree Claes
Journal:  Crit Care       Date:  2015-02-16       Impact factor: 9.097

6.  Comparison Between Carbapenems and β-Lactam/β-Lactamase Inhibitors in the Treatment for Bloodstream Infections Caused by Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae: A Systematic Review and Meta-Analysis.

Authors:  Maged Muhammed; Myrto Eleni Flokas; Marios Detsis; Michail Alevizakos; Eleftherios Mylonakis
Journal:  Open Forum Infect Dis       Date:  2017-05-16       Impact factor: 3.835

Review 7.  Piperacillin-tazobactam as alternative to carbapenems for ICU patients.

Authors:  Benoit Pilmis; Vincent Jullien; Alexis Tabah; Jean-Ralph Zahar; Christian Brun-Buisson
Journal:  Ann Intensive Care       Date:  2017-11-10       Impact factor: 6.925

8.  Epidemiology and Prognosis of Intensive Care Unit-Acquired Bloodstream Infection.

Authors:  Hatem Kallel; Stephanie Houcke; Dabor Resiere; Michaella Roy; Claire Mayence; Cyrille Mathien; Joy Mootien; Magalie Demar; Didier Hommel; Felix Djossou
Journal:  Am J Trop Med Hyg       Date:  2020-04-16       Impact factor: 2.345

9.  Optimal Empiric Polymyxin B Treatment of Patients Infected with Gram-Negative Organisms Detected Using a Blood Antimicrobial Surveillance Network in China.

Authors:  Xingbing Wu; Chen Huang; Hui Wang; Jinru Ji; Chaoqun Ying; Yonghong Xiao
Journal:  Drug Des Devel Ther       Date:  2021-06-17       Impact factor: 4.162

10.  Epidemiology of bloodstream infections in patients with acute myeloid leukemia undergoing levofloxacin prophylaxis.

Authors:  Francesco Giuseppe De Rosa; Ilaria Motta; Ernesta Audisio; Chiara Frairia; Alessandro Busca; Giovanni Di Perri; Filippo Marmont
Journal:  BMC Infect Dis       Date:  2013-12-01       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.